20 / 28
• Treatment with durvalumab after concurrent chemoradiation did not
worsen symptoms, function or global health status/QoL in patients with
locally advanced, unresectable NSCLC
• Change from baseline for key symptoms was minimal with both durvalumab and placebo
(change in score from baseline <±10)
• Clinically relevant improvements in alopecia and dysphagia was likely due to resolution of
toxicities related to prior chemoradiation
• Besides other pain and appetite loss, there were no between-group differences in time to
deterioration or improvement rates
• Alongside the efficacy and safety findings from PACIFIC, these data
further support the use of durvalumab in this disease setting
Summary and Conclusions